The Korean Journal of Medicine

  • 제86권3호
  • /
  • Pages.265-270
  • /
  • 2014
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

말라리아

Malaria

  • 염준섭 (성균관대학교 의과대학 내과학교실)
  • Yeom, Joon-Sup (Department of Internal Medicine, Sungkyunkwan University School of Medicine)
  • 발행 : 2014.03.01
⟨ 이전 논문 다음 논문 ⟩

초록

Vivax malaria has occurred every year since its re-emergence in 1993. The majority of malaria infections in the Republic of Korea occur among person living in the vivax malaria-risk area. In the early period, most of the cases were from soldiers stationed in the Demilitarized Zone. But since the year 2000, epidemiologic characteristics have changed. In 2013, 453 cases occurred which is the lowest number since 1996 and more than half of the annual cases are occurring from civilian. Although number of malaria infection occurring among persons who traveled to regions with ongoing malaria transmission is relatively small, imported malaria is the important health concern. Imported malaria infections, especially falciparum malaria can be fatal if not diagnosed and treated promptly with appropriate antimalarial drugs. Even though malaria chemoprophylaxis will prevent majority of malaria infection, majority of persons with imported malaria did not take chemoprophylaxis. For proper prescription of prophylactic antimalarial medications and treatment, clinicians should consider likely country of malaria acquisition and drug resistance situation of that country.

키워드

참고문헌

  1. Korea Centers for Disease Control and Prevention. 2013 Malaria Management Guidelines. 2013.
  2. Yeom JS, Ryu SH, Oh S, et al. Evaluation of anti-malarial effects of mass chemoprophylaxis in the Republic of Korea army. J Korean Med Sci 2005;20:707-712. https://doi.org/10.3346/jkms.2005.20.5.707
  3. Tiburskaja NA, Vrublevskaja OS. The Course of Infection Caused by the North Korean Strain of Plasmodium Vivax. Geneva: World Health Organization, 1977.
  4. Arnold J, Alving AS, Hockwald RS, Clayman CB, Dern RJ, Beutler E. Natural history of Korean vivax malaria after deliberate inoculation of human volunteers. J Lab Clin Med 1954;44:723-726.
  5. Nishiura H1, Lee HW, Cho SH, et al. Estimates of short- and long-term incubation periods of Plasmodium vivax malaria in the Republic of Korea. Trans R Soc Trop Med Hyg 2007;101:338-343. https://doi.org/10.1016/j.trstmh.2006.11.002
  6. Korea Centers for Disease Control and Prevention. Malaria Prevention Guidelines for Traveling Abroad, 2014.
  7. Kim HS, Kwok J, Yoon SK. Epidemiologic Characteristics of Imported Malaria in Korea 2003-2012: Public Health Weekly Report. Korea Centers for Disease Control and Prevention, 2014.
  8. Lee KS, Kim TH, Kim ES, et al. Chloroquine-resistant Plasmodium vivax in the Republic of Korea. Am J Trop Med Hyg 2009;80:215-217.
  9. Yeom JS, Jun G, Kim JY, et al. Status of Plasmodium vivax malaria in the Republic of Korea, 2008-2009: decrease followed by resurgence. Trans R Soc Trop Med Hyg 2012;106:429-436. https://doi.org/10.1016/j.trstmh.2012.03.011
  10. Baird JK. Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev 2009;22:508-534. https://doi.org/10.1128/CMR.00008-09
  11. Wongsrichanalai C1, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2002;2:209-218. https://doi.org/10.1016/S1473-3099(02)00239-6
  12. Fairhurst RM, Wellems TE. Plasmodium species (malaria). In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases.
  13. World Health Organization. Guidelines for the Treatment of Malaria. 2nd ed. Geneva: WHO, 2010. 7th ed. Philadelphia: Churchill Livingstone, 2010:3437-3462.
  14. Dondorp AM, Fairhurst RM, Slutsker L, et al. The threat of artemisinin-resistant malaria. N Engl J Med 2011;365:1073-1075. https://doi.org/10.1056/NEJMp1108322
  15. Witkowski B, Khim N, Chim P, et al. Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia. Antimicrob Agents Chemother 2013;57:914-923. https://doi.org/10.1128/AAC.01868-12
  16. Wilson ME, Weld LH, Boggild A, et al. Fever in returned travelers: results from the GeoSentinel Surveillance Network. Clin Infect Dis 2007;44:1560-1568. https://doi.org/10.1086/518173
  17. Huh AJ, Kwak YG, Kim ES, et al. Parasitemia characteristics of Plasmodium vivax malaria patients in the Republic of Korea. J Korean Med Sci 2011;26:42-46. https://doi.org/10.3346/jkms.2011.26.1.42
  18. Kim JY, Ji SY, Goo YK, et al. Comparison of rapid diagnostic tests for the detection of Plasmodium vivax malaria in South Korea. PLoS One 2013;8:e64353. https://doi.org/10.1371/journal.pone.0064353
  19. Shin SY, Yu JH, Kim JY, et al. A case of mixed malaria infection with severe hemolytic anemia after travel to Angola. Infect Chemother 2012;44:386-390. https://doi.org/10.3947/ic.2012.44.5.386
  20. Lee HJ, Park TS, Kim SS, et al. A clinical study of adverse reactions after taking mefloquine. Infect Chemother 2007;39:159-164.
  21. Kwon NH, Park TS, Kang HS, et al. Compliance with atovaquone-proguanil against malaria of Korean travelers abroad. Infect Chemother 2008;40:255-258. https://doi.org/10.3947/ic.2008.40.5.255
  22. John GK, Douglas NM, von Seidlein L, et al. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J 2012;11:280. https://doi.org/10.1186/1475-2875-11-280
  23. Centers for Disease Control and Preventions. Treatment of malaria (guidelines for clinicians) [Internet]. Atlanta (GA): Centers for Disease Control and Prevention, c2014 [cited 2014 Feb 20]. Available from: http://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf.